Merus (NASDAQ:MRUS) Earns “Buy” Rating from Guggenheim

Merus (NASDAQ:MRUS)‘s stock had its “buy” rating reiterated by Guggenheim in a note issued to investors on Tuesday,Benzinga reports. They currently have a $109.00 price objective on the biotechnology company’s stock. Guggenheim’s target price would suggest a potential upside of 132.22% from the stock’s previous close.

Other equities analysts also recently issued reports about the stock. Bank of America decreased their price objective on shares of Merus from $73.00 to $70.00 and set a “buy” rating on the stock in a report on Monday, March 10th. Wells Fargo & Company began coverage on shares of Merus in a report on Friday, February 7th. They issued an “overweight” rating and a $91.00 price objective on the stock. Citigroup upped their price objective on shares of Merus from $89.00 to $97.00 and gave the company a “buy” rating in a report on Monday, December 9th. HC Wainwright reiterated a “buy” rating and issued a $85.00 price objective on shares of Merus in a report on Monday, March 3rd. Finally, The Goldman Sachs Group began coverage on shares of Merus in a report on Thursday, November 21st. They issued a “buy” rating and a $73.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, fourteen have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Merus currently has a consensus rating of “Buy” and an average target price of $85.31.

Merus Price Performance

NASDAQ MRUS traded down $0.28 on Tuesday, hitting $46.94. 16,776 shares of the stock were exchanged, compared to its average volume of 631,350. The business’s fifty day moving average is $42.99 and its 200 day moving average is $46.28. Merus has a 52 week low of $37.77 and a 52 week high of $61.61. The company has a market capitalization of $3.24 billion, a PE ratio of -11.88 and a beta of 1.15.

Merus (NASDAQ:MRUS) last posted its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.48. Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. The firm had revenue of $9.14 million for the quarter, compared to analyst estimates of $10.57 million. Analysts predict that Merus will post -3.85 EPS for the current fiscal year.

Institutional Investors Weigh In On Merus

Large investors have recently bought and sold shares of the company. State of Wyoming acquired a new stake in Merus during the fourth quarter worth about $48,000. Wells Fargo & Company MN grew its stake in Merus by 27.3% during the fourth quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company’s stock worth $59,000 after buying an additional 300 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in Merus during the fourth quarter worth about $60,000. Avior Wealth Management LLC acquired a new stake in Merus during the fourth quarter worth about $76,000. Finally, Lazard Asset Management LLC acquired a new stake in Merus during the fourth quarter worth about $84,000. 96.14% of the stock is currently owned by institutional investors and hedge funds.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.